Patents by Inventor Maralee McVean
Maralee McVean has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8883477Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: GrantFiled: June 14, 2013Date of Patent: November 11, 2014Assignee: Kineta Two, LLCInventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Patent number: 8859251Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: GrantFiled: July 1, 2013Date of Patent: October 14, 2014Assignee: Kineta Two, LLCInventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Publication number: 20140005101Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: ApplicationFiled: June 14, 2013Publication date: January 2, 2014Applicant: Kineta Two LLCInventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Publication number: 20140005102Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: ApplicationFiled: July 1, 2013Publication date: January 2, 2014Applicant: Kineta Two LLCInventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Patent number: 8486678Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: GrantFiled: February 1, 2012Date of Patent: July 16, 2013Assignee: Kineta Two, LLCInventors: Shawn P Iadonato, Charles L Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Publication number: 20130157293Abstract: The invention describes methods for manufacturing oligoadenylate synthetase (OAS) proteins for use as active pharmaceutical ingredients in pharmaceutical compositions. A manufacturing method is described that produces large quantities of concentrated, highly active OAS protein for use in pharmaceutical compositions for the treatment of a variety of diseases including viral infection. Methods for monitoring and validating the manufacturing process are also described.Type: ApplicationFiled: September 6, 2012Publication date: June 20, 2013Applicant: Kineta Two, LLCInventors: MARK E BRANUM, Maralee McVean, Just Justesen, Eric J. Tarcha
-
Publication number: 20120258908Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: ApplicationFiled: February 1, 2012Publication date: October 11, 2012Applicant: KINETA TWO, LLCInventors: SHAWN P. IADONATO, CHARLES L. MAGNESS, MARK BRANUM, MARALEE MCVEAN, CHRISTINA SCHERER
-
Patent number: 8133710Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: GrantFiled: March 30, 2010Date of Patent: March 13, 2012Assignee: Kineta Two, LLCInventors: Shawn P Iadonato, Charles L Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Publication number: 20100256348Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: ApplicationFiled: March 30, 2010Publication date: October 7, 2010Applicant: ILLUMIGEN BIOSCIENCES, INC.Inventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Patent number: 7732177Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: GrantFiled: November 17, 2006Date of Patent: June 8, 2010Assignee: Illumigen Biosciences, Inc.Inventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Patent number: 7388112Abstract: The synthesis and use of a novel class of tumor necrosis factor (TNF?) inhibitors and immunomodulators are provided. Examples are those having the structures: wherein a, b and c are integers from 0 to 12, X equals NH or CHNH2, R1 and R2 each is a hydrogen or a C1 to C20 aliphatic; aliphatic amine; an alicyclic; aromatic; heterocycle; and halogenated forms thereof; and wherein, a, b and c are integers from 0 to 12; R1, R2, R3, and R4 each is a hydrogen or a C1 to C20; aliphatic amine; an alicyclic; aromatic; a heterocycle; and halogenated forms thereof.Type: GrantFiled: July 1, 2005Date of Patent: June 17, 2008Assignee: MediQuest Therapeutics, Inc.Inventors: Mark R. Burns, Maralee McVean, Kevin Kennedy, Arthur Yeung, Bruce H. Devens
-
Publication number: 20080124311Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: ApplicationFiled: November 17, 2006Publication date: May 29, 2008Applicant: Illumigen Biosciences, Inc.Inventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Publication number: 20080038753Abstract: The invention describes methods for manufacturing oligoadenylate synthetase (OAS) proteins for use as active pharmaceutical ingredients in pharmaceutical compositions. A manufacturing method is described that produces large quantities of concentrated, highly active OAS protein for use in pharmaceutical compositions for the treatment of a variety of diseases including viral infection. Methods for monitoring and validating the manufacturing process are also described.Type: ApplicationFiled: July 31, 2007Publication date: February 14, 2008Applicant: ILLUMIGEN BIOSCIENCES, INC.Inventors: Mark BRANUM, Maralee McVEAN, Just JUSTESEN, Eric TARCHA
-
Publication number: 20060167054Abstract: The synthesis and use of a novel class of tumor necrosis factor (TNF?) inhibitors and immunomodulators are provided. Examples are those having the structures: wherein a, b and c are integers from 0 to 12, X equals NH or CHNH2, R1 and R2 each is a hydrogen or a C1 to C20 aliphatic; aliphatic amine; an alicyclic; aromatic; heterocycle; and halogenated forms thereof; and wherein, a, b and c are integers from 0 to 12; R1, R2, R3, and R4 each is a hydrogen or a C1 to C20; aliphatic amine; an alicyclic; aromatic; a heterocycle; and halogenated forms thereof.Type: ApplicationFiled: July 1, 2005Publication date: July 27, 2006Applicant: MediQuest Therapeutics, Inc.Inventors: Mark Burns, Maralee McVean, Kevin Kennedy, Arthur Yeung, Bruce Devens
-
Patent number: 6919483Abstract: The synthesis and use of a novel class of tumor necrosis factor (TNF?) inhibitors and immunomodulators are provided. These compounds have pharmacological applications as well as uses in assays relating to TNF? and other involved cytokines. As pharmaceuticals, these compounds are used to treat inflammatory, infectious, autoimmune or other proliferative diseases and conditions related to the unwanted presence or activity of TNF? and/or one or more other involved cytokines, alone or in combination with other agents.Type: GrantFiled: May 23, 2003Date of Patent: July 19, 2005Assignee: Mediquest Therapeutics, Inc.Inventors: Mark R. Burns, Maralee McVean, Kevin J. Kennedy, Arthur Yeung, Bruce H. Devens
-
Publication number: 20040235960Abstract: The synthesis and use of a novel class of tumor necrosis factor (TNF&agr;) inhibitors and immunomodulators are provided. These compounds have pharmacological applications as well as uses in assays relating to TNF&agr; and other involved cytokines. As pharmaceuticals, these compounds are used to treat inflammatory, infectious, autoimmune or other proliferative diseases and conditions related to the unwanted presence or activity of TNF&agr; and/or one or more other involved cytokines, alone or in combination with other agents.Type: ApplicationFiled: May 23, 2003Publication date: November 25, 2004Inventors: Mark R. Burns, Maralee McVean, Kevin J. Kennedy, Arthur Yeung, Bruce H. Devens